SCHEMBL30922504

SCHEMBL30922504

CCOC(=O)CCCCc1c(C)cc2c(cnn2C2CCCCO2)c1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 1/20 0.35
▸ CYP4A11 Q02928 1/20 0.35
▸ RXRA P19793 1/20 0.35
▸ RXRB P28702 1/20 0.35
▸ RXRG P48443 1/20 0.35
▸ MGLL Q99685 1/20 0.34
▸ TBXAS1 P24557 1/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ L3MBTL1 Q9Y468 2/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ OPRD1 P41143 1/20 0.31
▸ HTR4 Q13639 1/20 0.31
▸ MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30923037 0.98 CYP4F2 (0.35) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30923128 0.92 RXRA (0.34) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30922853 0.90 RXRA (0.33) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30923075 0.90 KRAS (0.34) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30922446 0.89 RXRA (0.35) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30922886 0.88 RXRA (0.36) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL27299482 0.88 RXRA (0.36) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30922605 0.87 CYP4F2 (0.36) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30923003 0.87 RXRA (0.33) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30922796 0.87 RXRA (0.41) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598921-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2025-08-13 — — EP disclosed
WO-2024107686-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2024-05-23 — — WO disclosed
Send feedback